Regulus Therapeutics Inc (NASDAQ:RGLS)
Regulus Therapeutics Inc (NASDAQ:RGLS) has, in the past two days, moved of its $0.86 52-week low to reach above $1.25. One of the buyers of RGLS below $1 was their CEO, Joseph Hagan, who bought almost 220,000 shares at an average price of $0.91.
Regulus Therapeutics Inc (NASDAQ:RGLS) is a biotechnology company headquartered in San Diego, CA. The company focuses on developing microRNA therapies. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. Regulus Therapeutics has strategic alliance with AstraZeneca AB and Sanofi for the development and commercialization of microRNA therapeutics; and with Biogen Inc. on microRNA biomarkers for multiple sclerosis. The company also has a collaboration agreement with GSK LLC.
Six investment firms follow Regulus Therapeutics Inc (NASDAQ:RGLS). Their analysts are split evenly on the future of RGLS shares. Three rate the shares as a “Strong Buy” and three rate the shares as a “Hold”. Regulus’ financial history is not stellar. Shareholders have never seen a profit. In 2012 the company posted a per share loss of (-$2.12) which was followed by annual losses of (-$0.49), (-$1.29), (-$1.06). and (-$1.55) in 2016. Similarly, sales have been inconsistent for the biotech firm. Regulus posted sales of $12.7 million in 2012. Followed by sales of $$19.6 million, $7.7 million, $20.8 million, and, for 2016, $1.2 million.
RGLS shares have lost over 45% YTD, and lost over 66% for the year. However, the past week has seen the shares rise from its annual lows to gain almost 24%.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $RGLS and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.